SUN-397 - In-Vitro Properties of REGN24493, A Novel TSHR Blocking Mab for the Treatment of Graves' Disease and Thyroid Eye Disease

Co-Author(s)

• JL

  Jeehyun Lee, PhD

  Regeneron Pharmaceuticals, Inc.
  Tarrytown, United States
• YR

  Yonaton Ray, n/a

  Regeneron Pharmaceuticals, Inc.
  Tarrytown, United States
• YB

  Yaroslava Bulynko, PhD

  Regeneron Pharmaceuticals, Inc.
  Tarrytown, United States
• EG

  Elena Garnova, PhD

  Regeneron Pharmaceuticals, Inc.
  Tarrytown, United States
• JK

  Jee Hae Kim, PhD

  Regeneron Pharmaceuticals, Inc.
  Tarrytown, United States
• SM

  Santiago Mendez-Huergo, PhD

  Regeneron Pharmaceuticals, Inc.
  Tarrytown, United States

Abstract Poster Presenter(s)

• 

  Bristol Denlinger, Ph.D.

  REGENERON PHARM INC
  Tarrytown, NY, United States

Senior Author/Primary Investigator(s)

• BS

  Botir Sagdullaev, PhD

  Regeneron Pharmaceuticals, Inc.
  Tarrytown, United States